Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Inventory (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Inventory for 4 consecutive years, with $6.5 million as the latest value for Q1 2026.

  • For Q1 2026, Inventory rose 105.56% year-over-year to $6.5 million; the TTM value through Mar 2026 reached $6.5 million, up 105.56%, while the annual FY2025 figure was $5.5 million, 72.01% up from the prior year.
  • Inventory hit $6.5 million in Q1 2026 for Phathom Pharmaceuticals, up from $5.5 million in the prior quarter.
  • Across five years, Inventory topped out at $6.5 million in Q1 2026 and bottomed at $111000.0 in Q2 2023.
  • Average Inventory over 4 years is $2.8 million, with a median of $3.1 million recorded in 2024.
  • Year-over-year, Inventory soared 2702.7% in 2024 and then grew 16.07% in 2025.
  • Phathom Pharmaceuticals' Inventory stood at $1.2 million in 2023, then skyrocketed by 165.56% to $3.2 million in 2024, then soared by 72.01% to $5.5 million in 2025, then grew by 17.94% to $6.5 million in 2026.
  • According to Business Quant data, Inventory over the past three periods came in at $6.5 million, $5.5 million, and $3.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.